827P First real-life data on olaparib in 1st line (1stL) maintenance BRCA1/2 mutated epithelial ovarian cancer (EOC) in France: Descriptive analysis of 201 patients (pts) enrolled in the cohort temporary authorization for use (ATUc).
Saved in:
| Title: | 827P First real-life data on olaparib in 1st line (1stL) maintenance BRCA1/2 mutated epithelial ovarian cancer (EOC) in France: Descriptive analysis of 201 patients (pts) enrolled in the cohort temporary authorization for use (ATUc). |
|---|---|
| Authors: | Bellier, C.1 (AUTHOR), Gladieff, L.2 (AUTHOR), Le Du, F.3 (AUTHOR), Garnier Tixidre, C.4 (AUTHOR), Berton-Rigaud, D.5 (AUTHOR), Bonnard, C.6 (AUTHOR), Lahrache, A.6 (AUTHOR), Debbache, A.6 (AUTHOR), Kacher-Damache, A.6 (AUTHOR), Delplanque, M.7 (AUTHOR), Suau, D.7 (AUTHOR), Richard, A-C.7 (AUTHOR), Brenner, O.7 (AUTHOR), Lahouegue, A.7 (AUTHOR), Urbieta, M.6 (AUTHOR), Gavoille, C.8 (AUTHOR), Freyer, G.9 (AUTHOR), Floquet, A.10 (AUTHOR), Frank, S.11 (AUTHOR), Kfoury, M.12 (AUTHOR) |
| Source: | Annals of Oncology. 2020 Supplement 4, Vol. 31, pS623-S624. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2020.08.966 |
